使用以团队为基础的精准医学来推进对罕见遗传性脑疾病的理解
Steven U Walkley1,2, Sophie Molholm3,4,5, Bryen Jordan3,4
1Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. Steve.walkley@einsteinmed.edu.
Journal of neurodevelopmental disorders
|March 16, 2024
概括
行动IDD基因团队将家庭与研究人员联系起来,以推进罕见遗传疾病的理解. 这种合作赋予了家庭权力,丰富了对智力和发育障碍的科学发现.
科学领域:
- 遗传学和罕见疾病
- 智力和发育障碍 研究 研究 智力和发育障碍
- 多学科合作 跨学科合作
背景情况:
- 导致智力和发育残疾 (IDD) 的罕见遗传疾病给家庭和研究人员带来了独特的挑战.
- 有效的沟通和协作对于推动研究和理解这些条件至关重要.
研究的目的:
- 描述"IDD基因团队行动"的方法,这是一个新的多学科倡议.
- 促进受罕见遗传IDD影响的家庭,临床医生和基础科学家之间的合作.
- 探索该模型在罕见疾病研究中更广泛应用的潜力.
主要方法:
- "IDD基因团队行动"模式召集了家庭,医生和科学家.
- 家庭分享个人和医疗史;医生讨论临床影响;科学家提供可访问的生物教程.
- 讨论包括潜在的治疗方法,并专注于特定的基因变异.
主要成果:
- 家庭表示深切的感激,并被授权建立特定条件的基础.
- 研究人员更深入地了解患者的挑战,从而影响研究方向.
- 研究通常集中在参与儿童中发现的基因变异上,这导致了新的合作.
结论:
- "Operation IDD Gene Team"模型为家庭和研究人员带来了积极的结果,促进了合作,加速了罕见疾病研究.
- 罕见疾病作为了解基本生物过程和常见疾病的关键模型.
- 这种方法有可能适用于各种各样的罕见遗传疾病,适用于所有年龄段的人.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).


